
Opinion|Videos|February 18, 2025
The Future of Neurokinin-Targeted Therapies in Patients With VMS
Author(s)Alexa N. Fiffick, D.O., MBS, MSCP
A panelist discusses how neurokinin-targeted therapies can be strategically combined with existing treatments to address multiple vasomotor symptoms (VMS) while highlighting their positive impact on patient quality of life, noting ongoing needs for long-term safety data and improved accessibility.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- How might these therapies fit into combination treatment strategies, and what combinations seem most promising?
- How do you see the broader implications of neurokinin-targeted therapies on patient outcomes and quality of life? What are the unmet needs with these therapies?
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
1,700 sites closed, 77,000 fewer children received PEPFAR-supported treatment after PEPFAR disruption | IAS 2026
2
Payers lean on step therapy, formulary exclusions as IRA reshapes Part D benefit design
3
Redemplo cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia
4
Step therapy requirements drive up time, costs in DME patients | ASRS 2026
5























